Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect

In this case report, we present a patient who suffered ceftaroline-associated encephalopathy, while receiving ceftaroline for acute bacterial skin and skin structure infections (aBSSSIs) that resolved after cessation of the suspected agent. We recommend close monitoring for encephalopathy in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Srinivasan, Aswin, Bennie, Blake, Viroliya, Krina, Kesavan, Ramesh, Sarva, Siva T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169127/
https://www.ncbi.nlm.nih.gov/pubmed/34094755
http://dx.doi.org/10.7759/cureus.14795
_version_ 1783701996725862400
author Srinivasan, Aswin
Bennie, Blake
Viroliya, Krina
Kesavan, Ramesh
Sarva, Siva T
author_facet Srinivasan, Aswin
Bennie, Blake
Viroliya, Krina
Kesavan, Ramesh
Sarva, Siva T
author_sort Srinivasan, Aswin
collection PubMed
description In this case report, we present a patient who suffered ceftaroline-associated encephalopathy, while receiving ceftaroline for acute bacterial skin and skin structure infections (aBSSSIs) that resolved after cessation of the suspected agent. We recommend close monitoring for encephalopathy in patients with creatinine clearance (CrCl) of <50 mL/min receiving ceftaroline.
format Online
Article
Text
id pubmed-8169127
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-81691272021-06-04 Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect Srinivasan, Aswin Bennie, Blake Viroliya, Krina Kesavan, Ramesh Sarva, Siva T Cureus Internal Medicine In this case report, we present a patient who suffered ceftaroline-associated encephalopathy, while receiving ceftaroline for acute bacterial skin and skin structure infections (aBSSSIs) that resolved after cessation of the suspected agent. We recommend close monitoring for encephalopathy in patients with creatinine clearance (CrCl) of <50 mL/min receiving ceftaroline. Cureus 2021-05-01 /pmc/articles/PMC8169127/ /pubmed/34094755 http://dx.doi.org/10.7759/cureus.14795 Text en Copyright © 2021, Srinivasan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Srinivasan, Aswin
Bennie, Blake
Viroliya, Krina
Kesavan, Ramesh
Sarva, Siva T
Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect
title Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect
title_full Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect
title_fullStr Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect
title_full_unstemmed Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect
title_short Ceftaroline-Associated Encephalopathy: A Rare Adverse Effect
title_sort ceftaroline-associated encephalopathy: a rare adverse effect
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169127/
https://www.ncbi.nlm.nih.gov/pubmed/34094755
http://dx.doi.org/10.7759/cureus.14795
work_keys_str_mv AT srinivasanaswin ceftarolineassociatedencephalopathyarareadverseeffect
AT bennieblake ceftarolineassociatedencephalopathyarareadverseeffect
AT viroliyakrina ceftarolineassociatedencephalopathyarareadverseeffect
AT kesavanramesh ceftarolineassociatedencephalopathyarareadverseeffect
AT sarvasivat ceftarolineassociatedencephalopathyarareadverseeffect

Ejemplares similares